# Cooper Companies (The) **Source:** https://geo.sig.ai/brands/cooper-companies-the **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** coopercos.com **Last Updated:** 2026-04-14 ## Summary San Ramon CA contact lenses and fertility devices (NASDAQ: COO) $3.87B FY2024 revenue (+9%); CooperVision MiSight myopia management, CooperSurgical IVF consumables, competing with J&J Vision and Alcon. ## Company Overview The Cooper Companies, Inc. is a San Ramon, California-based medical device company — publicly traded on the NASDAQ (NASDAQ: COO) as an S&P 500 Health Care component — operating two segments: CooperVision (soft contact lenses for vision correction globally — the second-largest contact lens manufacturer worldwide) and CooperSurgical (fertility and women's health medical devices including IVF laboratory consumables, assisted reproductive technology products, and gynecological surgical instruments) through approximately 15,000 employees in 130 countries. In fiscal year 2024 (ending October 2024), Cooper Companies reported revenues of $3.87 billion (+9% organic growth), with CooperVision generating $2.56 billion from daily, biweekly, and monthly contact lens sales across sphere, toric (astigmatism-correcting), and multifocal (presbyopia-correcting) lens categories, and CooperSurgical generating $1.31 billion from fertility clinic consumables and women's health surgical products. CEO Albert White has executed CooperVision's strategy of capturing the premium daily silicone hydrogel lens market: silicone hydrogel material (higher oxygen permeability improving eye health versus conventional hydrogel) commands a 20-30% price premium over conventional daily lenses, and Cooper's MyDay (premium daily silicone hydrogel) and clariti (value silicone hydrogel) brands compete across price tiers against Johnson & Johnson Vision's Acuvue Oasys and CIBA Vision's AIR OPTIX brands for the global market shift toward dailies — the fastest-growing contact lens modality as patients prefer the convenience and hygiene of discarding lenses after each day's wear. Cooper Companies' contact lens and fertility technology model creates competitive advantages through the specialized manufacturing technology for precision medical optics and the fertility clinic infrastructure relationships: manufacturing soft contact lenses at CooperVision's scale (2+ billion lenses per year) requires precision polymer molding and quality control to tolerances of ±0.25 diopter across billions of individual lens units — a manufacturing capability that took decades to develop at scale and creates significant entry barriers for new competitors. The myopia management lens category (MiSight — FDA-approved daily contact lens clinically proven to slow myopia progression in children) represents CooperVision's highest-growth and highest-margin product line, positioning CooperVision as the category creator in a pediatric contact lens market addressing the global myopia epidemic (increasing rates of childhood nearsightedness in Asia and Western populations). CooperSurgical's fertility business (cryopreservation media, embryo culture systems, genetic testing consumables for IVF laboratories) benefits from the structural growth of assisted reproduction as IVF procedure volumes grow 5-7% annually as fertility rates decline and IVF success rates improve. In 2025, Cooper Companies competes in soft contact lenses against Johnson & Johnson Vision (NYSE: JNJ, Acuvue brand — contact lens market leader), Alcon (NYSE: ALC, DAILIES Total1 and AIR OPTIX lenses), and Bausch + Lomb (NYSE: BLCO, Ultra lenses) for daily disposable lens market share, myopia management lens adoption in pediatric optometry, and toric/multifocal premium lens positioning with eye care professionals. The myopia management market — MiSight's competition against Ortho-K rigid gas permeable lenses (worn overnight to temporarily reshape the cornea), atropine eye drop protocols, and Essilor Stellest spectacle lenses designed to slow myopia progression — represents a multi-treatment modality competitive landscape where evidence and practitioner training differentiate product adoption. CooperSurgical's ParaGard IUD (copper intrauterine device — non-hormonal contraception) and SAGE ART Compass electronic medical record for IVF clinics provide anchor products in the women's health and fertility adjacent markets. The 2025 strategy focuses on MiSight myopia management global expansion (particularly Asia Pacific where myopia prevalence and awareness are highest), daily silicone hydrogel lens volume growth, and CooperSurgical fertility consumables growth as IVF procedure volume expands globally. ## Frequently Asked Questions ### What does The Cooper Companies do? The Cooper Companies is a global medical device company operating through two specialized divisions: CooperVision, one of the world's leading manufacturers of soft contact lenses serving customers in over 100 countries, and CooperSurgical, which provides medical devices, fertility products, and genomic services for women's health and reproductive care. With over 16,000 employees in 130+ countries, Cooper helps people experience life's beautiful moments through innovative vision correction and comprehensive women's healthcare solutions. ### Who are The Cooper Companies' customers and target market? The Cooper Companies serves two distinct customer bases: CooperVision serves eye care professionals (optometrists and ophthalmologists) and contact lens wearers globally with approximately 25% market share in the U.S., while CooperSurgical serves obstetricians, gynecologists, reproductive endocrinologists, fertility clinics, and women's healthcare providers with medical devices, IVF products, and fertility services. Combined, these divisions reach millions of patients worldwide seeking vision correction or reproductive and women's healthcare solutions. ### When was The Cooper Companies founded? The Cooper Companies was founded in 1958 by Parker Montgomery as Cooper Laboratories in Palo Alto, California. The company was incorporated as Cooper Tinsley Laboratories Inc. in 1961, renamed Cooper Laboratories Inc. in 1967, and restructured as The Cooper Companies, Inc. in 1987. The company entered the contact lens business in 1972 through the acquisition of British lens maker GlobalVision, and established CooperSurgical as a dedicated business unit in 1990. ### Where is The Cooper Companies based and where does it operate? The Cooper Companies is headquartered in San Ramon, California, at 6101 Bollinger Canyon Road. The company operates globally with over 16,000 employees in more than 130 countries across the Americas, Europe, Asia-Pacific, the Middle East, and Africa. CooperVision has its headquarters in Pleasanton, California, with manufacturing facilities, distribution centers, R&D sites, and commercial offices worldwide. Additional major U.S. offices include locations in Trumbull, CT; Victor, NY; Rochester, NY; and Cranford, NJ. ### What is The Cooper Companies' valuation and financial performance? The Cooper Companies (NYSE: COO) has a market capitalization of approximately $14.62-17.98 billion as of 2024-2025. The company reported fiscal 2024 revenue of $3.90 billion (up 8.41% year-over-year) with earnings of $392.30 million (up 33.34%). Non-GAAP diluted EPS reached $3.69 (up 15%). Analyst consensus rates Cooper stock as 'Buy' with a 12-month price target of $79.27, reflecting confidence in the company's growth trajectory across both divisions. ### What makes The Cooper Companies different from competitors? The Cooper Companies differentiates through its focused specialization in two high-growth medical device markets: contact lenses and women's health. CooperVision is the only major contact lens manufacturer offering daily disposable silicone hydrogel lenses across the full vision correction spectrum (sphere, toric, multifocal) through its clariti brand. CooperSurgical provides the most comprehensive medical device coverage over the entire IVF cycle combined with fertility services through Generate Life Sciences, offering an integrated solution no competitor matches. The company's culture of innovation earned recognition as a Best Workplace for Innovators by Fast Company. ### Who are The Cooper Companies' main competitors? In contact lenses, CooperVision competes with Johnson & Johnson Vision Care, Alcon, and Bausch & Lomb—together these four companies account for the majority of the global contact lens market, with Cooper holding approximately 25% U.S. market share. In women's health and fertility, CooperSurgical competes with specialized medical device companies across different product categories including Hologic, Boston Scientific (women's health devices), and various fertility service providers. Cooper's comprehensive IVF coverage and integrated fertility services platform provides competitive differentiation. ### How can I contact The Cooper Companies? The Cooper Companies' corporate headquarters is located at 6101 Bollinger Canyon Road, Suite 500, San Ramon, California 94583. For investor relations and corporate information, visit www.coopercos.com. For CooperVision contact lens products and eye care professional resources, visit www.coopervision.com. For CooperSurgical medical devices and fertility products, visit www.coopersurgical.com. The company maintains customer service and support centers globally to serve healthcare professionals and patients in 130+ countries. ### Is The Cooper Companies hiring and what career opportunities exist? Yes, The Cooper Companies actively recruits talent globally across manufacturing, R&D, commercial operations, clinical affairs, and corporate functions. With over 16,000 employees in 130+ countries, Cooper offers diverse career opportunities in medical device innovation, vision science, women's health, and fertility services. The company was recognized as a Great Place to Work for three consecutive years and named to America's Greatest Workplaces for Diversity and Women. Cooper emphasizes belonging, professional development, and family-focused benefits in its culture. ### What's the latest news about The Cooper Companies? Recent developments include: (1) Record fiscal 2024 results with $3.90 billion revenue and strong growth across both divisions; (2) August 2024 acquisition of obp Surgical for $100 million expanding surgical device portfolio; (3) June 2024 acquisition of ZyMot Fertility for $34 million adding innovative sperm separation technology; (4) Partnership with The Conceive Fertility Foundation's 2025 IVF grant program; (5) Recognition as Best Workplace for Innovators and multiple workplace awards; and (6) Pressure from activist investor Jana Partners to explore strategic alternatives including potential combination of the contact lens unit. ### What is The Cooper Companies' market position? The Cooper Companies holds strong market positions in both operating segments: CooperVision ranks as the third-largest soft contact lens manufacturer globally with approximately 25% U.S. market share, competing with industry leaders Johnson & Johnson, Alcon, and Bausch & Lomb. CooperSurgical has established leadership in women's health and fertility with the most comprehensive medical device coverage across the IVF cycle. Cooper is a publicly traded company on NASDAQ (ticker: COO) and serves customers in over 130 countries with fiscal 2024 revenue of $3.90 billion. ### What are The Cooper Companies' future plans and strategic priorities? The Cooper Companies' strategic priorities include: (1) Continuing innovation in contact lens technology with focus on daily disposable silicone hydrogel platforms; (2) Expanding CooperSurgical's fertility and women's health portfolio through organic growth and strategic acquisitions; (3) Integrating recent acquisitions including obp Surgical and ZyMot Fertility to capture synergies; (4) Investing in digital health and connected fertility solutions; (5) Expanding geographic reach particularly in emerging markets; (6) Advancing sustainability initiatives as demonstrated by inclusion in Dow Jones Sustainability Index; and (7) Maintaining focus on innovation culture while evaluating strategic alternatives in response to activist investor input. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*